ARTICLE | Clinical News

Cimzia certolizumab pegol: Postmarketing study started

January 9, 2012 8:00 AM UTC

UCB began the single-blind, international postmarketing EXXELERATE trial comparing Cimzia plus methotrexate vs. Humira plus methotrexate for 104 weeks in about 900 patients who have responded inadequately to methotrexate and who have not previously received anti-TNF treatment. After 12 weeks, non-responders will switch to the alternative therapy for the duration of the trial. ...